Article Details

Belantamab Mafodotin–Based PFS Benefits in Difficult-to-Treat R/R Myeloma Subgroups

Retrieved on: 2024-07-01 13:06:37

Tags for this article:

Click the tags to see associated articles and topics

Belantamab Mafodotin–Based PFS Benefits in Difficult-to-Treat R/R Myeloma Subgroups. View article details on hiswai:

Excerpt

... monoclonal antibody—basically daratumumab. This means that at the ... monoclonal antibodies, then transplant and maintenance with lenalidomide.

Article found on: www.onclive.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up